메뉴 건너뛰기




Volumn 13, Issue 1, 2011, Pages 72-77

Big changes are coming in hepatitis C

Author keywords

Boceprevir; Direct acting antivirals; Hepatitis C; Pegylated interferon; Polymerase inhibitors; Protease inhibitors; Ribavirin; Telaprevir

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

EID: 79551525326     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-010-0153-9     Document Type: Article
Times cited : (16)

References (23)
  • 1
    • 0022868893 scopus 로고
    • Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon
    • 1:STN:280:DyaL2s%2FmsV2gsw%3D%3D 10.1056/NEJM198612183152503 3097544
    • JH Hoofnagle KD Mullen BD Jones, et al. 1986 Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon N Engl J Med 315 1575 1578 1:STN:280:DyaL2s%2FmsV2gsw%3D%3D 10.1056/NEJM198612183152503 3097544
    • (1986) N Engl J Med , vol.315 , pp. 1575-1578
    • Hoofnagle, J.H.1    Mullen, K.D.2    Jones, B.D.3
  • 2
    • 0024509701 scopus 로고
    • Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
    • 1:CAS:528:DyaL1MXit1Khtrk%3D 10.1126/science.2523562 2523562
    • QL Choo G Kuo AJ Weiner, et al. 1989 Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 359 362 1:CAS:528:DyaL1MXit1Khtrk%3D 10.1126/science.2523562 2523562
    • (1989) Science , vol.244 , pp. 359-362
    • Choo, Q.L.1    Kuo, G.2    Weiner, A.J.3
  • 4
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
    • DOI 10.1016/S0140-6736(01)06102-5
    • MP Manns JG McHutchison SC Gordon, et al. 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958 965 1:CAS:528:DC%2BD3MXntF2qtb8%3D 10.1016/S0140-6736(01)06102-5 11583749 (Pubitemid 32913521)
    • (2001) Lancet , vol.358 , Issue.9286 , pp. 958-965
    • Manns, M.P.1    McHutchison, J.G.2    Gordon, S.C.3    Rustgi, V.K.4    Shiffman, M.5    Reindollar, R.6    Goodman, Z.D.7    Koury, K.8    Ling, M.-H.9    Albrecht, J.K.10
  • 5
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    • 1:CAS:528:DC%2BD38Xnt12rtb0%3D 10.1056/NEJMoa020047 12324553
    • MW Fried ML Shiffman KR Reddy, et al. 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982 1:CAS:528:DC%2BD38Xnt12rtb0%3D 10.1056/NEJMoa020047 12324553
    • (2002) N Engl J Med , vol.347 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 6
    • 79551505543 scopus 로고
    • Genetic organization and diversity of the hepatitis C virus
    • QL Choo KH Richman JH Han, et al. 1994 Genetic organization and diversity of the hepatitis C virus Virol 68 4420 4426
    • (1994) Virol , vol.68 , pp. 4420-4426
    • Choo, Q.L.1    Richman, K.H.2    Han, J.H.3
  • 7
    • 68249154875 scopus 로고    scopus 로고
    • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
    • 1:CAS:528:DC%2BD1MXps1Kjuro%3D 10.1056/NEJMoa0808010 19625712
    • JG McHutchison EJ Lawitz ML Shiffman, et al. 2009 Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 580 593 1:CAS:528:DC%2BD1MXps1Kjuro%3D 10.1056/NEJMoa0808010 19625712
    • (2009) N Engl J Med , vol.361 , pp. 580-593
    • McHutchison, J.G.1    Lawitz, E.J.2    Shiffman, M.L.3
  • 8
    • 0024238272 scopus 로고
    • Synthetic peptides as substrates and inhibitors of human immune deficiency virus-1 protease
    • 1:CAS:528:DyaL1MXitVemtg%3D%3D 3056930
    • S Billich MT Knoop J Hansen, et al. 1988 Synthetic peptides as substrates and inhibitors of human immune deficiency virus-1 protease J Biol Chem 263 17905 17908 1:CAS:528:DyaL1MXitVemtg%3D%3D 3056930
    • (1988) J Biol Chem , vol.263 , pp. 17905-17908
    • Billich, S.1    Knoop, M.T.2    Hansen, J.3
  • 10
    • 59149103099 scopus 로고    scopus 로고
    • Protease and polymerase inhibitors for the treatment of hepatitis C
    • 10.1111/j.1478-3231.2008.01928.x 19207967
    • T Asselah Y Benhamou P Marcellin 2009 Protease and polymerase inhibitors for the treatment of hepatitis C Liver Int 29 Suppl 1 57 67 10.1111/j.1478-3231. 2008.01928.x 19207967
    • (2009) Liver Int , vol.29 , Issue.SUPPL. 1 , pp. 57-67
    • Asselah, T.1    Benhamou, Y.2    Marcellin, P.3
  • 11
    • 77956268467 scopus 로고    scopus 로고
    • Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT 1): An open-label, randomised, multicentre phase 2 trial
    • 1:CAS:528:DC%2BC3cXhtVymt7zP 10.1016/S0140-6736(10)60934-8 20692693
    • PY Kwo EJ Lawitz J McCone, et al. 2010 Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT 1): an open-label, randomised, multicentre phase 2 trial Lancet 376 705 716 1:CAS:528:DC%2BC3cXhtVymt7zP 10.1016/S0140-6736(10)60934-8 20692693
    • (2010) Lancet , vol.376 , pp. 705-716
    • Kwo, P.Y.1    Lawitz, E.J.2    McCone, J.3
  • 13
    • 28844451934 scopus 로고    scopus 로고
    • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    • DOI 10.1016/j.jhep.2005.10.003, PII S0168827805006677
    • S Zeuzem M Buti P Ferenci, et al. 2006 Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia J Hepatol 44 97 103 1:CAS:528:DC%2BD2MXht12ktLjL 10.1016/j.jhep.2005.10.003 16290907 (Pubitemid 41772522)
    • (2006) Journal of Hepatology , vol.44 , Issue.1 , pp. 97-103
    • Zeuzem, S.1    Buti, M.2    Ferenci, P.3    Sperl, J.4    Horsmans, Y.5    Cianciara, J.6    Ibranyi, E.7    Weiland, O.8    Noviello, S.9    Brass, C.10    Albrecht, J.11
  • 19
    • 65449152185 scopus 로고    scopus 로고
    • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    • 1:CAS:528:DC%2BD1MXlsVGmtrc%3D 10.1056/NEJMoa0806104 19403902
    • JG McHutchison GT Everson SC Gordon, et al. 2009 Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 1827 1838 1:CAS:528:DC%2BD1MXlsVGmtrc%3D 10.1056/NEJMoa0806104 19403902
    • (2009) N Engl J Med , vol.360 , pp. 1827-1838
    • McHutchison, J.G.1    Everson, G.T.2    Gordon, S.C.3
  • 20
    • 77953416889 scopus 로고    scopus 로고
    • Review: New direct-acting antivirals in the development for hepatitis C virus infection
    • 1:CAS:528:DC%2BC3cXhs1akur%2FO 10.1177/1756283X10363055
    • P Pockros 2010 Review: New direct-acting antivirals in the development for hepatitis C virus infection Therapeutic Adv Gastroenterol 3 191 202 1:CAS:528:DC%2BC3cXhs1akur%2FO 10.1177/1756283X10363055
    • (2010) Therapeutic Adv Gastroenterol , vol.3 , pp. 191-202
    • Pockros, P.1
  • 21
    • 78049460599 scopus 로고    scopus 로고
    • HCV treatment-related anemia is associated with higher sustained virologic response rate
    • • (Epub ahead of print). This article provides a clinical description of the correlation of anemia and sustained virologic response. Anemia is not always a bad thing
    • • Sulkowski MS, Shiffman ML, Afdhal NH, et al.: HCV treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010 (Epub ahead of print). This article provides a clinical description of the correlation of anemia and sustained virologic response. Anemia is not always a bad thing.
    • (2010) Gastroenterology
    • Sulkowski, M.S.1    Shiffman, M.L.2    Afdhal, N.H.3
  • 22
    • 77949773445 scopus 로고    scopus 로고
    • ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
    • 1:CAS:528:DC%2BC3cXit1SmtLo%3D 10.1038/nature08825 20173735 This important paper outlines a gene variant responsible for protecting against ribavirin-induced anemia
    • J Fellay AJ Thompson D Ge, et al. 2010 ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C Nature 464 405 408 1:CAS:528:DC%2BC3cXit1SmtLo%3D 10.1038/nature08825 20173735 This important paper outlines a gene variant responsible for protecting against ribavirin-induced anemia
    • (2010) Nature , vol.464 , pp. 405-408
    • Fellay, J.1    Thompson, A.J.2    Ge, D.3
  • 23
    • 77953881002 scopus 로고    scopus 로고
    • Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
    • 1:CAS:528:DC%2BC3cXpsFait7s%3D 10.1053/j.gastro.2010.04.013 20399780 This landmark clinical paper describes the power of the IL-28B polymorphism and its effect on interferon response between ethnicities. Much of the lower response in black patients is explained by this finding
    • AJ Thompson AJ Muir MS Sulkowski, et al. 2010 Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 120 129 1:CAS:528:DC%2BC3cXpsFait7s%3D 10.1053/j.gastro. 2010.04.013 20399780 This landmark clinical paper describes the power of the IL-28B polymorphism and its effect on interferon response between ethnicities. Much of the lower response in black patients is explained by this finding
    • (2010) Gastroenterology , vol.139 , pp. 120-129
    • Thompson, A.J.1    Muir, A.J.2    Sulkowski, M.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.